Somatotroph comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-23. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
The report also noted that between 1960 and 1980, China's state propaganda chose to publish "gray-cover books" (Chinese: 灰皮书, romanized: huī pí shū), a large range of socialist and anti-socialist foreign literature criticizing the Soviet system. These included Leon Trotsky's The Revolution Betrayed and Stalin, works of Eduard Bernstein and Karl Kautsky, Milovan Djilas' The New Class, and Friedrich Hayek's The Road to Serfdom. The report suggested these publications influenced interest in the Soviet failures among Chinese leaders Xi, Jiang, and Deng Xiaoping.
== Affiliated hospitals == Rajindra Hospital, Patiala with 1009 beds was attached to the college in early 1951. The hospital was equipped with all the latest apparatus and instruments to make it fit for imparting clinical teaching to the students. Two well designed, spacious and well lighted lecture theatres equipped with arrangements for epidiascopes projections and audio visual aids were provided on the hospital side in addition to four lecture theatres of similar design on college side for basic departments. The department of Tuberculosis and Respiratory Medicine/Pulmonary Medicine is located in a separate campus, known as the Tuberculosis Centre, Patiala which started functioning on 25 July 1953 with 22 observation beds, 11 for male and 11 for female patients with Tuberculosis. It is popularly known as TB Hospital or Padma Shri Dr. Khushdeva Singh Chest Diseases Hospital, and currently has a capacity of 121 beds. Primary health centres at Bhadson, Kauli and Tripuri are attached with this college for teaching purposes. There are three hostels, two for girls and one for boys. In addition to this there is one hostel in the Rajindra Hospital also for Doctors/Interns/House surgeons. The college has a very spacious auditorium, big play ground and an open-air theatre. The college is governed by Director Research and Medical Education, Punjab and is affiliated to Baba Farid University of Health Sciences, Faridkot.
Optical microscopy Scanning electron microscopy (SEM) Transmission electron microscopy (TEM) Field ion microscopy (FIM) Scanning probe microscopy (SPM) Atomic force microscopy (AFM) Scanning tunneling microscopy (STM) X-ray diffraction topography (XRT) Atom-Probe Tomography (APT)
=== Mergers and acquisitions === In 1981, Tetra Pak relocated its corporate headquarters to Lausanne, Switzerland, for tax reasons, but retained all research in Lund, Sweden. For the equivalent of US$2.5 billion, Tetra Pak acquired Alfa-Laval AB in 1991, a Swedish company producing industrial and agricultural equipment and milk separators, world-leading in its industry, in what was at the time Sweden's largest takeover. Since the deal allowed Tetra Pak to integrate Alfa Laval processing know-how, the merger made it possible for Tetra Pak to offer packaging and processing solutions. The deal drew anti-competitive scrutiny from the European Commission, but it was approved after various concessions from both companies. After the merger with Alfa Laval, Tetra Pak announced plans to return its headquarters to Sweden, and in 1993 Tetra Laval Group was created with dual headquarters in Lund and Lausanne. Alfa Laval's liquid processing unit was absorbed into Tetra Pak and the unit specialising in dairy production machinery was organised separately as Alfa Laval Agri. Alfa Laval Agri was later renamed DeLaval, after Alfa Laval's founder Gustaf de Laval, and is still a part of the Tetra Laval group. The part of Alfa Laval that was not directly linked to Tetra Pak's activities – heat exchangers and separation equipment among others – was sold in 2000 to Swedish finance group Industri Kapital. In 2001, Tetra Laval acquired the French plastic packaging group Sidel.
Sources: en.wikipedia.org
Excimer lasers emitting in ultraviolet and vacuum ultraviolet wavelength ranges are widely used in many industries. Argon-fluoride excimer lasers operating at 193 nm are routinely used in integrated circuit production by photolithography. Coherent sources are available down to a wavelength limit around 126 nm, characteristic of the Ar2* excimer laser. Direct UV-emitting laser diodes are available at 375 nm. UV diode-pumped solid state lasers have been demonstrated using cerium-doped lithium strontium aluminum fluoride crystals (Ce:LiSAF), a process developed in the 1990s at Lawrence Livermore National Laboratory. Wavelengths shorter than 325 nm are commercially generated in diode-pumped solid-state lasers. Ultraviolet lasers can also be made by applying frequency conversion to lower-frequency lasers. Ultraviolet lasers have applications in industry (laser engraving), medicine (dermatology, and keratectomy), chemistry (MALDI), free-space optical communication, computing (optical storage), and manufacture of integrated circuits.
Athletes are adults ... and they have a right to do with their body what they wish – my body, my choice; your body, your choice, ... And no government, no paternalistic sports federation, should be making those decisions for athletes – particularly around products that are FDA regulated and approved.
=== Sexual effects === From the available evidence, it seems men who have been circumcised with the aid of a circumcision device experience unchanged or heightened sexual pleasure and satisfaction. There is some evidence such men also derive long time improvements in erectile function. The accumulated data show circumcision has no adverse physiological effect on sexual pleasure, function, desire, or fertility. There is some evidence that circumcision has no effect on pain with intercourse, premature ejaculation, intravaginal ejaculation latency time, erectile dysfunction, or difficulties with orgasm. There are popular misconceptions that circumcision benefits or adversely affects the sexual pleasure of the circumcised person. According to a 2014 review, the effect of circumcision on sexual partners' experiences is unclear as it has not been well studied. According to a policy statement by the Canadian Paediatric Society that was reaffirmed in 2021, "medical studies do not support circumcision as having an impact on sexual function or satisfaction for partners of circumcised individuals".
==== Phycobilins ==== Phycobilins are a third group of pigments found in cyanobacteria, and glaucophyte, red algal, and cryptophyte chloroplasts. Phycobilins come in all colors, though phycoerytherin is one of the pigments that makes many red algae red. Phycobilins often organize into relatively large protein complexes about 40 nanometers across called phycobilisomes. Like photosystem I and ATP synthase, phycobilisomes jut into the stroma, preventing thylakoid stacking in red algal chloroplasts. Cryptophyte chloroplasts and some cyanobacteria don't have their phycobilin pigments organized into phycobilisomes, and keep them in their thylakoid space instead.
We were only supposed to carry four passengers ... We had six." According to Maluțan, it was 12:08 when they left for Snagov. After they arrived there, Ceaușescu took Maluțan into the presidential suite and ordered him to get two helicopters filled with soldiers for an armed guard, and a further Dauphin to come to Snagov. Maluțan's unit commander replied on the phone, "There has been a revolution ... You are on your own ... Good luck!" Maluțan then said to Ceaușescu that the second motor was now warmed up and they needed to leave soon but he could only take four people, not six. Mănescu and Bobu stayed behind. Ceaușescu ordered Maluțan to head for Titu. Near Titu, Maluțan says that he received the national flights denial and had to land to not get shot down by the army. He did so in a field next to the old road that led to Pitești. Maluțan then told his four passengers that he could do nothing more. The Securitate men ran to the roadside and began to flag down passing cars. Two cars stopped, one of them driven by a forestry official and one a red Dacia driven by a local doctor. However, the doctor was not happy about getting involved and, after a short time driving the Ceaușescus, faked engine trouble. A bicycle repairman was then flagged down and drove them in his car to Târgoviște. The repairman, Nicolae Petrișor, convinced them that they could hide in an agricultural technical institute on the edge of town. When they arrived, the director there guided the Ceaușescus into a room and then locked them in.
Sources: en.wikipedia.org
=== Uptake === Glucose binds to the taste receptor for sweetness on the human tongue, specifically, the proteins T1R2 and T1R3, thus allowing human to identify glucose-containing food sources. Glucose mainly comes from food—about 300 g (11 oz) per day is produced by conversion of food, but it is also synthesized from other metabolites in the body's cells. In humans, the breakdown of glucose-containing polysaccharides happens in part already during chewing by means of amylase, which is contained in saliva, as well as by maltase, lactase, and sucrase on the brush border of the small intestine. Glucose is a building block of many carbohydrates and can be split off from them using certain enzymes. Glucosidases, a subgroup of the glycosidases, first catalyze the hydrolysis of long-chain glucose-containing polysaccharides, removing terminal glucose. In turn, disaccharides are mostly degraded by specific glycosidases to glucose. The names of the degrading enzymes are often derived from the particular poly- and disaccharide; among other things, for the degradation of polysaccharide chains there are amylases (named after amylose, a component of starch), cellulases (named after cellulose), chitinases (named after chitin), and more. Furthermore, for the cleavage of disaccharides, there are maltase, lactase, sucrase, trehalase, and others. In humans, about 70 genes are known that code for glycosidases. They have functions in the digestion and degradation of glycogen, sphingolipids, mucopolysaccharides, and poly (ADP-ribose) polymerases.
=== CKD-EPI formula === The CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula was first published in May 2009. It was developed in an effort to create a formula more accurate than the MDRD formula, especially when actual GFR is greater than 60 mL/min per 1.73 m2. This is the formula recommended as of 2014 by NICE in the UK. Researchers pooled data from multiple studies to develop and validate this new equation. They used 10 studies that included 8254 participants, randomly using 2/3 of the data sets for development and the other 1/3 for internal validation. Sixteen additional studies, which included 3896 participants, were used for external validation. The CKD-EPI equation performed better than the MDRD (Modification of Diet in Renal Disease Study) equation, especially at higher GFR, with less bias and greater accuracy. When looking at NHANES (National Health and Nutrition Examination Survey) data, the median estimated GFR was 94.5 mL/min per 1.73 m2 vs. 85.0 mL/min per 1.73 m2, and the prevalence of chronic kidney disease was 11.5% versus 13.1%. Despite its overall superiority to the MDRD equation, the CKD-EPI equations performed poorly in certain populations, including black women, the elderly and the obese, and was less popular among clinicians than the MDRD estimate. The 2009 CKD-EPI equation is:
==== Live ==== Doillon's band includes François Poggio on the guitar, Nicolas Subrechicot on keys, Pierre Lavandon on bass and Franck M'Bouéké on the drums. In May 2016, Doillon was chosen by John Cale to perform "Femme Fatale" during his tribute show to the Velvet Underground at the Philharmonie de Paris, alongside Mark Lanegan, Saul Williams, Animal Collective, Étienne Daho and The Libertines. In 2017, Doillon participated in the homage to Leonard Cohen at the MAC, alongside Jarvis Cocker, Chilly Gonzales and Half Moon Run, producing a cover of "Famous Blue Raincoat". On 3 October 2017, for the 3 Ring Circus with John Grant and Richard Hawley, Doillon performed three acoustic sets by herself at three different venues. On 6 October 2017, she repeated this performance in Sheffield, with Hawley and James Dean Bradfield.
=== Laboratory methods === In general, on the typical laboratory scale, the direct reaction of a haloalkane with sodium hydrosulfide is inefficient owing to the competing formation of sulfides (overalkylation). Instead, alkyl halides are converted to thiols via an S-alkylation of thiourea. This multistep, one-pot process proceeds via the intermediacy of the isothiouronium salt, which is hydrolyzed in a separate step:
Because of its behavior as a prodrug and its pharmacokinetic differences, lisdexamfetamine has a longer duration of therapeutic effect than immediate-release dextroamphetamine and shows reduced misuse potential. CYP2D6, dopamine β-hydroxylase (DBH), flavin-containing monooxygenase 3 (FMO3), butyrate-CoA ligase (XM-ligase), and glycine N-acyltransferase (GLYAT) are the enzymes known to metabolize amphetamine or its metabolites in humans. Amphetamine has a variety of excreted metabolic products, including 4-hydroxyamphetamine, 4-hydroxynorephedrine, 4-hydroxyphenylacetone, N-hydroxyamphetamine, benzoic acid, hippuric acid, norephedrine, and phenylacetone. Among these metabolites, the active sympathomimetics are 4-hydroxyamphetamine, 4-hydroxynorephedrine, norephedrine, and N-hydroxyamphetamine. The main metabolic pathways involve aromatic para-hydroxylation, aliphatic alpha- and beta-hydroxylation, N-oxidation, N-dealkylation, and deamination. The known metabolic pathways, detectable metabolites, and metabolizing enzymes in humans include the following:
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.